A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00096928
Show 182 Study Locations
|Study Director:||Ivor Caro, M.D.||Genentech, Inc.|